41 results about "Diazoxide" patented technology

The present invention discloses a treatment for syndrome-X, and resulting complications, that include hyperlipidemia, hypertension, central obesity, hyperinsulinemia and impaired glucose intolerance. Diabetic complications include excess proinsulin levels.

This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicty of neutoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.

Provided are immediate or prolonged administration of certain salts of K_ATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K_ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

Provided are immediate or prolonged administration of certain salts of K_ATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K_ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

Provided are immediate or prolonged administration of certain salts of K_ATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K_ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

The invention belongs to the technology of medical biology and relates to organ preservative fluid and the method for making same. The procedure to prepare 1000ml of the fluid is as follows, tetrahydrobiopterin 1.57mg and diazoxide 6.92mg are dissolved in 1ml of dimethyl sulfoxide to act as mother liquid, CaCl2 of 0.1mol/L is prepared for backup, double distilled water 800ml is charged in a container of 1000ml, KCl 1.12g, MgCl2 2.64g, manna sugar 10.93g, histidine 4.63g, glutathion 0.92g and glutavene 3.74g are sequentially charged and agitated to limpidity, 6.90ml of sodium lactate is charged and agitated to limpidity, CaCl2 2.5ml of 0.1mol/L is charged and agitated to limpidity, and backup liquid and mother liquid are charged and agitated to limpidity. The pH is adjusted to 7.3-7.5, the osmotic pressure is adjusted to 320Osm/L, and the volume of double distilled water is set to 1000ml. The fluid is stored in low temperature of 4 DEG C.

A composition including diazoxide (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine-1,1-dioxide) for the treatment and/or prevention of retinal ischemia and of diseases associated with retinal ischemia. The composition can also contain riluzole, a derivative active in neuroprotection of the latter, or a pharmaceutically acceptable salt of the latter.

The invention relates to the use of diazoxide or a pharmaceutically acceptable salt thereof at low doses to treat a CNS autoimmune demyelinating disease selected from selected from multiple sclerosis (MS), clinically isolated syndrome (CIS), tumefactive (tumor-like) M S, Marburg's acute M S, Balós's concentric sclerosis, acute disseminated encephalomyelitis (ADEM), post-vaccinal encephalitis (PVE), post-infectious encephalomyelitis (PIE) and neuromyelitis optica (NMO).

This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicity of neurotoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be utilized to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.

The invention discloses a method for preparing diazoxide. The method comprises the following steps: reacting o-aminobenzenesulfonamide with N-chlorosuccinimide in a chlorine solvent to obtain 2-amino-5-chlorobenzenesulfonamide, mixing the 2-amino-5-chlorobenzenesulfonamide, an imidazolium salt and an amide solvent, and heating the obtained mixture to react to obtain the diazoxide; or mixing o-aminobenzenesulfonamide, the imidazolium salt and the amide solvent, heating for a reaction to obtain a compound IV, and reacting the compound IV with N-chlorosuccinimide in the chlorine solvent so as toobtain the diazoxide. The invention also discloses an application of imidazole hydrochloride as a catalyst in the preparation of diazoxide. The method avoids the problems that chlorosulfonyl isocyanate and strong acid (sulfuric acid) which have high corrosivity and toxicity are used in the reaction process and the reaction temperature is high (240-250 DEG C), and the reaction steps are short; thetotal yield of the two steps can reach 90% or above; and compared with publicly reported diazoxide preparation methods, the synthesis method of the invention overcomes numerous defects, so that the synthesis method is suitable for industrial production.

The present invention relates to the use of a potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof, wherein the fasting and/or postabsorptive plasma insulin level is reduced to about 5 mU/l or less. The present invention also relates to the use of a potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof for treating or preventing obesity, obesity related disorders and conditions and other disorders and conditions related to weight gain in a mammal in need thereof, said method comprising orally administering to said mammal in need thereof a daily dosage of about 5 mg to about 1200 mg, calculated on a Diazoxide active weight basis.

The invention discloses a novel pharmaceutical application of a potassium ATP channel regulator, namely application of the potassium ATP channel regulator (such as diazoxide, crocarine, pinadil, niacdil, alplecarine and the like) in preparation of a medicine for resisting diabetic nephropathy. The invention further provides application of a pharmaceutical composition taking the potassium ATP channel regulator as an active ingredient in prevention or treatment of diabetic nephropathy. A diabetic rat is modeled through streptozotocin (STZ), high fat diet is given to the rat after modeling to form the diabetic nephropathy, whether the rat enters the diabetic nephropathy or not is detected by taking microalbuminuria (mALB) as an index, and whether the model succeeds or not is observed by taking the weight and blood sugar level of the rat as indexes. Experimental results show that after the potassium ATP channel opener such as diazoxide is administered to the diabetic rat, the renal injury process of the diabetic rat can be delayed.

A pharmaceutical preparation treats Friedreich's ataxia and treats or prevents pathologies related thereto. In particular, the pharaceutical preparation concerns the use of diazoxide or 7-chloro-3-methyl-4H-1,2,4 benzothiadiazine 1,1-dioxide, in combination with glucose and/or leucine, for the treatment of Friedreich's ataxia (FRDA) and for the treatment or prevention of pathologies related thereto.

Disclosed is a diazaoxa heterocyclic spiro-dione piperazine alkaloid derivative having an antiviral activity and a preparation method thereof. The compound is a compound of formula (I), has anti-RSV, HSV-1 and EV71 activities and has the following structure: wherein R1, R2, R3, R4 are each independently selected from optionally substituted H, alkyl, cycloalkyl, alkylacyl, alkoxyacyl, cycloalkylacyl, alkenyl, alkenylacyl, alkynyl, alkynylacyl, aryl, arylalkyl, arylacyl, heteroaryl, heteroarylalkyl, heteroarylacyl, saturated or unsaturated heterocyclyl, saturated or unsaturated heterocyclylalkyl, saturated or unsaturated heterocyclylacyl; n is 0 or 1; and a chemical bond (A) represents a bond (B) that points into the page or a bond (C) that points out of the page. "-----" indicates a single bond or does not exist, and when "-----" represents a single bond, R1 and R2 do not exist.